本研究的主要目的是比较 nivolumab 联合 ipilimumab 对比标准治疗（SOC）（sorafenib 或 lenvatinib）于所有未曾接受过全身性治疗的晚期肝细胞癌（HCC）随机参与者中的总生存期（OS）。
适应症：Hepatocellular Carcinoma
入组条件
纳入标准
- Participants must have a diagnosis of HCC based on histological confirmation
- Participants must have an advanced HCC
- Participants must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable previously untreated lesion
- Child-Pugh score 5 or 6
- Eastern Cooperative Oncology Group (ECOG) performance status(PS) 0 or 1
排除标准
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Prior liver transplant
- Episodes of hepatic encephalopathy (greater than or equal to \[\>=\] Grade 2) within 12 months prior to randomization
- Active brain metastases or leptomeningeal metastases
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。